Cell No. : Cell Name
RCB5962 : HUDEP-2-CY1
update : 2024/10/11
|
| Comment | Currently not ready. |
| Comment from the depositor | A derivative cell line of HUDEP-2 in which thalassemia mutations are introduced, i.e., homozygous for the HBB IVSI-110 (G>A) mutation (HGVS name; HBB:c.93-21G>A). |
| Terms and conditions | |
| Remarks | |
| Order Form |
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Expected time |
Upon a request we will start preparation. Contact us: cellkitaku.brc@riken.jp
|
| IPR |
The Cyprus Foundation for Muscular Dystrophy Research (Cyprus) & RIKEN BioResource Research Center (Japan)
|
| Reference information |
Reference |
3
|
| User's Publication |
0
|
| Reference |
|
18128
Papaioannou NY, Patsali P, Naiisseh B, Papasavva PL, Koniali L, Kurita R, Nakamura Y, Christou S, Sitarou M, Mussolino C, Cathomen T, Kleanthous M, Lederer CW.
High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis
Front Genome Ed
2023
5:1141618
PubMed ID: 36969374
DOI: 10.3389/fgeed.2023.1141618
|
|
18129
Papasavva P, Kleanthous M, Lederer CW.
Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases
Mol Diagn Ther
2019
23(2):201-222
PubMed ID: 30945166
DOI: 10.1007/s40291-019-00392-3
|
|
6742
Kurita R, Suda N, Sudo K, Miharada K, Hiroyama T, Miyoshi H, Tani K, Nakamura Y.
Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells.
PLoS One
2013
8(3):e59890
PubMed ID: 23533656
DOI: 10.1371/journal.pone.0059890
|
Back
Top
CELL BANK Website